en · de · es · fr · pt
analytical-notes.peptides6823.com › Blog › Cjc-1295 Structure And Mechanism — Quick Reference

Cjc-1295 Structure And Mechanism — Quick Reference

By Editorial Desk · published 2025-12-15 · last reviewed 2026-01-01 · Blog

GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.

CJC-1295 Structure And Mechanism

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Structure And Receptor Pharmacology

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Cjc-1295 at a glance

PropertyValueNotes
Physical formLyophilized white powderSupplied as a freeze-dried solid for research use
Molecular weightApproximately 3,647 Da (DAC form)Lower for the variant lacking the albumin-binding moiety
SolubilitySoluble in water and aqueous bufferTypically dissolved in sterile or bacteriostatic water
Typical storage temperature−20 °C or belowDry powder, desiccated and protected from light
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity estimation and identity confirmation

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Related pages on this site

Receptor Action and Pharmacokinetics

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Notes from published material

=== Pharmacodynamics === As a glucocorticoid, the lipophilic structure of prednisolone allows for easy passage through the cell membrane where it then binds to its respective glucocorticoid receptor (GCR) located in the cytoplasm. Upon binding, the formation of the GC/GCR complex causes dissociation of chaperone proteins from the glucocorticoid receptor enabling the GC/GCR complex to translocate inside the nucleus. This process occurs within 20 minutes of binding. Once inside the nucleus, the homodimer GC/GCR complex binds to specific DNA binding sites known as glucocorticoid response elements (GREs) resulting in gene expression or inhibition. Complex binding to positive GREs leads to the synthesis of anti-inflammatory proteins while binding to negative GREs blocks the transcription of inflammatory genes. They inhibit the release of signals that promote inflammation such as nuclear factor-Kappa B (NF-κB), Activator protein 1 (AP-1), nuclear factor of activated T-cells (NFAT), and stimulate anti-inflammatory signals such as the interleukin-10 gene. All of them will collectively cause a sequence of events, including the inhibition of prostaglandin synthesis and additional inflammatory mediators. Glucocorticoids also inhibit neutrophil cell death and demargination. As well as phospholipase A2, which in turn lessens arachidonic acid derivative genesis.

A conductance deduced from the resulting current between the electrodes and the voltages is reported as ESC, measured in microsiemens (μS), and is proportional to the Cl− flow to the skin surface, that is to say the ability to secrete Cl− ions by eccrine glands, thus providing a quantitative measurement of sudomotor function. The measurement requires no specific patient preparation or medical personnel training. The test lasts less than 3 minutes, and is innocuous and non-invasive. In general, decreased ESC values indicate a higher risk of sudomotor dysfunction, and thus a greater likelihood of small fiber neuropathy. Sudoscan has been shown to be useful in the detection of small fiber neuropathy in patients with and without type 2 diabetes mellitus (T2DM) with a sensitivity of 77 to 87% and a specificity of 67 to 92%, as well as in the screening of diabetic nephropathy. Sudoscan has been compared with other reference tests including Heart Rate Variability (HRV) indices, intraepidermal nerve fiber density, sweat gland nerve fiber density and quantitative sudomotor axon reflex testing (QSART). In addition to diabetes, low ESC values have been reported in association with increased severity of diabetic kidney disease and metabolic syndrome. It has also been shown to be sensitive to change after different interventions in subjects with T2DM. ESC measurements are highly reproducible. Studies have shown ESC values to be dependent on ethnicity. For that purpose, normative reference values have been established on a total of 1,350 healthy participants.

=== Raman spectroscopy === Raman spectroscopy is a spectroscopic technique that provides non-destructive analysis capable of identifying components within mixtures with chemical specificity without complex sample preparation. Raman spectroscopy relies on photon scattering following visible light radiation, where the shift in photon energies corresponds to information about the system's vibrational modes and their frequencies. Upon obtaining vibrational modenfrequencies, qualitative classifications about the system can be both made and reinforced. Raman spectroscopy works well in parallel with microfluidic devices for many qualitative biological applications. For some applications, Raman spectroscopy is preferred over other detection methods such as infrared (IR) spectroscopy as water has a strong interference signal with IR but not with Raman. Likewise, methods such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), mass spectrometry (MS), or gas chromatography (GC) are also not ideal as these methods require larger sample sizes. Since microfluidics enables experiments with small volumes (including analysis of single cells or few cells), Raman is a leading microfluidic detection method. Specifically, Raman integration with microfluidic devices has strong applications in systems where lipid identification is necessary, common in biofuel research. For example, a lipid fluorescent assay is not selective enough and thus cannot identify molecular differences the way Raman can through molecular vibrations.

Those who perform floor and other surface cleaning tasks (e.g., floor waxing) and who use quaternary ammonium, alcohol, and chlorine-based products are associated with a higher VOC exposure than the two previous groups, that is, they are particularly linked to exposure to acetone, chloroform, α-pinene, 2-propanol or d-limonene. Other healthcare environments such as nursing and age care homes have been rarely a subject of study, even though the elderly and vulnerable populations may spend considerable time in these indoor settings where they might be exposed to VOCs, derived from the common use of cleaning agents, sprays and fresheners. In one study, more than 200 chemicals were identified, of which 41 have adverse health effects, 37 of them being VOCs. The health effects include skin sensitization, reproductive and organ-specific toxicity, carcinogenicity, mutagenicity, and endocrine-disrupting properties. Furthermore, in another study carried out in the same European country, it was found that there is a significant association between breathlessness in the elderly population and elevated exposure to VOCs such as toluene and o-xylene, unlike the remainder of the population.

Sources: en.wikipedia.org

Background from the literature

==== Specialty selection ==== The Swedish medical specialty system is, as of 2015, made up of three different types of specialties; base specialties, subspecialties, and add-on specialties. Every physician wishing to specialize starts by training in a base specialty and can thereafter go on to train in a subspecialty specific to their base specialty. Add-on specialties also require previous training in a base specialty or subspecialty but are less specific in that they, unlike subspecialties, can be entered into through several different previous specialties. Furthermore, the base specialties are grouped into eight classes—pediatric specialties, imaging and functional medicine specialties, independent base specialties, internal medicine specialties, surgical specialties, laboratory specialties, neurological specialties, and psychiatric specialties. It is a requirement that all base specialty training programs are at least five years in length. Common reasons for base specialty training taking longer than five years is paternity or maternity leave or simultaneous Ph.D. studies.

He also serves on the scientific advisory board for seven additional companies (Eisai, Kemxtree, Quanta Therapeutics, Inc., Alkermes, Inc, Nutcracker Therapeutics, Inc., Hongene Biotech Corporation, Shouxin, and Sage Therapeutics) and has consulted for over twenty more, including presently at Bristol-Meyers-Squibb, Gilead, and BASF Corporation. In 2014, Baran began a partnership with IKA, a laboratory equipment manufacturer, to bring to market equipment designed to standardize electrochemical protocols and make electrochemistry accessible to the average organic chemist. Three years after the partnership began, the ElectraSyn was presented at the American Chemical Society annual meeting. In the seven years since, the ElectraSyn and subsequent ElectraSyn 2.0 have been adopted by the synthetic community and utilized towards hundreds of research articles and patents.

=== Template synthesis === The template synthesis method uses a nanoporous membrane template composed of cylindrical pores of uniform diameter to make fibrils (solid nanofiber) and tubules (hollow nanofiber). This method can be used to prepare fibrils and tubules of many types of materials, including metals, semiconductors and electronically conductive polymers. The uniform pores allow for control of the dimensions of the fibers so nanofibers with very small diameters can be produced through this method. However, a drawback of this method is that it cannot make continuous nanofibers one at a time.

For example, in one 6-week study, the median time to achieving consistent response was 29 days. Likewise, complete excretion of the drug may take several weeks. During the first week after treatment discontinuation, the brain concentration of fluoxetine decreases by only 50%, The blood level of norfluoxetine four weeks after treatment discontinuation is about 80% of the level registered by the end of the first treatment week, and, seven weeks after discontinuation, norfluoxetine is still detectable in the blood.

The historian Michael Zimmermann who knew Peukert as an undergraduate in the early 1970s described Peukert as active in the student federation MSB Spartakus and the DKP, but described him as a committed Communist who grew disillusioned following the expulsions of Rudolf Bahro and Wolf Biermann together with the "freeze" on discussing Euro-communism within the party following orders from East Germany. Peukert's writings on German Communist resistance in Nazi Germany differed greatly from the party line laid down in East Germany that the entire German working class under the KPD had opposed the Nazi regime, and ultimately led to him leaving the Communist Party in 1978 to join the Social Democratic party. The DKP was secretly subsidized by East Germany and as a result, the party was slavishly loyal to its East German paymasters. Peukert during his time in the Communist party had come to find the party line on history was too dogmatic and rigid as he kept finding the facts of history were more complex and nuanced than the version of history laid by the party line. Peukert's work was criticized within Communist circles for his willingness to be critical of the decisions of the underground KPD in Nazi Germany, and his sensitivity to "human frailty" as he examined working class life in the Third Reich, writing that not everybody wanted to be a hero and die for their beliefs. Peukert's first book was his 1976 book Ruhrarbeiter gegen den Faschismus (Ruhr Workers Against Fascism), a study of anti-Nazi activities among the working class of the Ruhr during the Third Reich.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 differ from modified GRF(1-29)?

The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.

Is CJC-1295 an approved medicine?

It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.

What is known about its half-life?

Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

Network